Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments

Expert Rev Clin Pharmacol. 2023 Feb;16(2):97-99. doi: 10.1080/17512433.2023.2174524. Epub 2023 Jan 29.

Authors

Georgios Polychronopoulos¹, Achilleas Papagiannis¹, Konstantinos Tziomalos¹

Affiliation

¹ First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece.

PMID: 36710460
DOI: 10.1080/17512433.2023.2174524

No abstract available

Keywords: Lipoprotein(a); SLN360; cardiovascular disease; olpasiran; pelacarsen.

Publication types

Editorial

MeSH terms

Cardiovascular Diseases*
Humans
Hypolipidemic Agents / pharmacology
Hypolipidemic Agents / therapeutic use
Lipoprotein(a)*
Risk Factors

Substances

Lipoprotein(a)
Hypolipidemic Agents